T1	Participants 316 391	patients undergoing lower third molar surgical extraction with bone removal
T2	Participants 393 488	Patients who qualified for the prospective, randomized, double-masked, placebo-controlled trial
T3	Participants 530 613	(1) single dose of oral clindamycin administered preoperatively (single-dose group)
T4	Participants 619 706	clindamycin administered preoperatively with continued therapy for 5 days (5-day group)
T5	Participants 716 731	a placebo group
T6	Participants 946 1060	86 patients (31 in the single-dose group, 28 in the 5-day group and 27 in the placebo group) enrolled in the study
T7	Participants 1062 1214	There were no statistically significant differences in postoperative inflammatory complications in patients during the first and second days postsurgery
T8	Participants 1216 1306	A statistically significant variation in body temperature was reported on the seventh day.
T9	Participants 1307 1428	Analysis of the postoperative analgesic intake did not show statistically significant differences between examined groups
T10	Participants 1430 1646	Clindamycin applied in a single preoperative dose of 600 mg with or without subsequent 5-day therapy does not demonstrate efficacy in prophylaxis for postoperative inflammatory complications after third molar surgery
